News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

E. Kelly Hester, PharmD

Advertisement

Articles by E. Kelly Hester, PharmD

Antiretroviral Safety in Pregnancy: Focus on Dolutegravir, Integrase Inhibitors, and Neural Tube Defects

ByE. Kelly Hester, PharmD,Celeste Caulder, PharmD
August 13th 2019

There has been increasing interest in the association between neural tube defects, dolutegravir, and integrase inhibitors as a class since 4 cases were reported in 2018.

Advertisement

Latest Updated Articles

  • Antiretroviral Safety in Pregnancy: Focus on Dolutegravir, Integrase Inhibitors, and Neural Tube Defects
    Antiretroviral Safety in Pregnancy: Focus on Dolutegravir, Integrase Inhibitors, and Neural Tube Defects

    Published: August 13th 2019 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up

2

Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?

3

Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP

4

Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us